Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies

SIMPLE SUMMARY: Venetoclax has proven to be a promising therapy for newly diagnosed, relapsed and refractory AML patients ineligible for induction chemotherapy. Current ongoing clinical trials are evaluating its effectivity as frontline therapy for all acute myeloid leukemia (AML) patients. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffioen, Mila S., de Leeuw, David C., Janssen, Jeroen J. W. M., Smit, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318140/
https://www.ncbi.nlm.nih.gov/pubmed/35884517
http://dx.doi.org/10.3390/cancers14143456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318140/
https://www.ncbi.nlm.nih.gov/pubmed/35884517
http://dx.doi.org/10.3390/cancers14143456

Ejemplares similares